2024 Annual Meeting | Industry Therapeutic Update from Eli Lilly and Company: Beyond the Surface: A Case Review Using Amyloid PET in Patients With Suspected Alzheimer’s Disease
Date
Monday 04/15/24
Time
11:45 AM - 12:45 PM MDT
Add To Calendar
Location
Colorado Convention Center | Bluebird 2A
Session Format
This program will be presented both in-person and online
On Demand
This program is not expected to be available in the meeting's On Demand product.
Event Type
Industry Therapeutic Update
Director(s)
Phillip Kuo
Topic(s)
General Neurology, Aging, Dementia, and Behavioral Neurology
Learning Objectives
An Expert-led clinical discussion on a new therapy for early symptomatic Alzheimer’s disease. This program is NOT accredited for continuing education by any organization. Additionally, Industry Therapeutic Updates program content and the views expressed herein are those of the presenting corporate entity and not of the AAN. These programs are not an official part of the 2024 AAN Annual Meeting education or scientific programs, nor are they endorsed by the AAN. The AAN cannot affirm claims pertaining to FDA off-label medication, research use of pre-FDA drugs, or other research information that might be discussed. Industry Therapeutic Updates are industry events.
CME Available
No CME available
Program Materials
Program Evaluations
Event Timeline
11:45 AM - 12:45 PM MDT
Speaker
Industry Therapeutic Update from Eli Lilly and Company: Beyond the Surface: A Case Review Using Amyloid PET in Patients With Suspected Alzheimer’s Disease
Faculty Disclosures
Phillip Kuo
No disclosure on file